This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Endo (ENDP) Files for Bankruptcy Amid Litigations, Huge Debt
by Zacks Equity Research
Endo (ENDP) finally files for bankruptcy after negotiations with its debtholders as litigation claims continue to weigh on the business.
Endo International (ENDP) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 118.75% and 9.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -21.31% and 9.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada
by Zacks Equity Research
Endo's (ENDP) subsidiary, Endo Ventures, signs agreement with Quoin Pharmaceuticals for developing/commercializing the latter's pipeline candidate, QRX003, for treating Netherton syndrome in Canada.
Endo (ENDP) Phase II Study for Frozen Shoulder Disappoints
by Zacks Equity Research
Endo (ENDP) mid-stage study of collagenase clostridium histolyticum (or CCH) for treating frozen shoulder disappoints.
Why Endo (ENDP) Stock Wilted After its Surge on Tuesday?
by Zacks Equity Research
Endo International (ENDO) tanks 26%, cooling off after its massive stock price surge on Tuesday, post the Supreme Court's decision to overturn Roe v. Wade.
Endo (ENDP) Inks Deal for Osteoarthritis Knee Pain Drug
by Zacks Equity Research
Endo (ENDP) collaborates with Taiwan Liposome to commercialize TLC599, an extended and controlled release liposomal formulated dexamethasone for chronic knee osteoarthritis (OA) pain.
Endo (ENDP) Crashes 46.54% as it Looks to Restructure Debt
by Zacks Equity Research
Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.
Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 Results
by Zacks Equity Research
Endo (ENDP) tops Q1 earnings and sales estimates. However, Vasostrict faces generic competition and the guidance for Q2 is dismal.
Endo International (ENDP) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 50% and 1.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
by Zacks Equity Research
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
Can Endo (ENDP) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Endo International (ENDP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Endo International (ENDP) closed at $2.12, marking a -0.93% move from the previous day.
Analysts Estimate Endo International (ENDP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Endo International (ENDP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Endo International (ENDP) closed the most recent trading day at $2.46, moving -1.2% from the previous trading session.
Endo International (ENDP) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Endo International (ENDP) closed at $2.31 in the latest trading session, marking no change from the prior day.
Why Is Endo (ENDP) Up 4.6% Since Last Earnings Report?
by Zacks Equity Research
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Endo International (ENDP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Endo International (ENDP) closed at $2.38 in the latest trading session, marking a -1.65% move from the prior day.
Endo International (ENDP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Endo International (ENDP) closed at $2.13, marking a -1.39% move from the previous day.
Endo (ENDP) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Endo (ENDP) tops Q4 earnings and sales estimates. However, Vasostrict faces generic competition, and the ongoing COVID-19 driven market conditions affect specialty product office-based procedures.
Endo (ENDP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Endo's (ENDP) fourth-quarter earnings might have gained from higher sales of Xiaflex.
Analysts Estimate Endo International (ENDP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Endo International (ENDP) Stock Moves -0.65%: What You Should Know
by Zacks Equity Research
Endo International (ENDP) closed at $3.08 in the latest trading session, marking a -0.65% move from the prior day.
Can Endo (ENDP) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Endo International (ENDP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Endo International (ENDP) closed at $3.14, marking a +1.95% move from the previous day.